Article -> Article Details
Title | Growth Hormone Deficiency Market Will Expand in the Coming Decade as Per Report |
---|---|
Category | Fitness Health --> Home Health |
Meta Keywords | Growth Hormone Deficiency Market |
Owner | vinit |
Description | |
Market Highlights Global Growth
Hormone Deficiency Market is expected to have a market value of
USD 5,243.3 Million by 2027. Growth Hormone Deficiency (GHD) is a rare type of disorder
where the pituitary gland produces an insufficient secretion of growth hormone
in the body. GHD can be congenital or developed in a later stage. Segment Analysis Global Growth Hormone Deficiency Market is classified into a
brand such as Norditropin, Genotropin, Humatrope, Saizen, Omnitrope, and
others. In addition, the global growth hormone deficiency market, by
application, is segmented into pediatric growth hormone deficiency, Turner
syndrome, Idiopathic Short Stature (ISS), small for gestational age, adult
growth hormone deficiency, Prader-Willi syndrome, and others. By route of
administration, the market is segmented into subcutaneous, intravenous, and
intramuscular. The global growth hormone market is segmented by the
distribution channel into hospital pharmacies, retail pharmacies, online pharmacies,
and specialty pharmacies Regional Analysis Global Growth Hormone Deficiency Market, based on region,
has been divided into the Americas, Europe, Asia-Pacific, and Rest of the
World. The Americas is classified into North America. North America
is further categorized into the US Canada and Latin America. The growth hormone
deficiency market in the US is expected to hold a major share owing to the
growing prevalence of growth hormone deficiency and Turner syndrome,
affordability of costly hormonal therapy, and the presence of a
well-established healthcare sector. Asia-Pacific is anticipated to be the fastest-growing market
owing to the growing healthcare expenditure and the presence of a large patient
pool. Growing investments in the region due to increasing demand are expected
to contribute to the market growth. For instance, in March 2017, Novo Nordisk
initiated a phase 3 clinical trial of somapacitan (NNC0195-0092) for Adult
Growth Hormone Deficiency (AGHD) in Japan. Additionally, the rising awareness
about the efficiency of growth hormone therapy in short stature is likely to
increase the demand for growth hormone products in this region.
The Middle East and Africa region includes the Middle East
& Africa. Increasing healthcare expenditure, rising investments by major
market players, and growing patient pool in this region are attributing to the
market growth. For instance, according to the International Trade
Administration, health expenditure in the UAE was USD 17 billion in 2017 and is
likely to reach USD 21.3 billion by 2021. Key Findings of the Study
|